Is QTTB or CGEM more profitable?

Q32 Bio's return on equity of 50.17% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Cullinan Therapeutics N/A -52.89% -48.18%

Does the media favor QTTB or CGEM?

In the previous week, Cullinan Therapeutics had 13 more articles in the media than Q32 Bio. MarketBeat recorded 17 mentions for Cullinan Therapeutics and 4 mentions for Q32 Bio. Cullinan Therapeutics' average media sentiment score of 0.69 beat Q32 Bio's score of 0.20 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cullinan Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, QTTB or VOR?

Q32 Bio has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 5.84 $29.82M $3.00 3.51 Vor Biopharma N/A N/A N/A N/A N/A

Is QTTB or VOR more profitable?

Q32 Bio's return on equity of 50.17% beat Vor Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Vor Biopharma N/A N/A N/A

Does the media favor QTTB or VOR?

In the previous week, Q32 Bio had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Q32 Bio and 2 mentions for Vor Biopharma. Q32 Bio's average media sentiment score of 0.20 beat Vor Biopharma's score of 0.00 indicating that Q32 Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RARE or QTTB?

In the previous week, Ultragenyx Pharmaceutical had 32 more articles in the media than Q32 Bio. MarketBeat recorded 36 mentions for Ultragenyx Pharmaceutical and 4 mentions for Q32 Bio. Ultragenyx Pharmaceutical's average media sentiment score of 0.74 beat Q32 Bio's score of 0.20 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 12 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Q32 Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ORIC or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.35% -33.39% Q32 Bio N/A 50.17% 29.49%

Does the media favor ORIC or QTTB?

In the previous week, Q32 Bio had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 4 mentions for Q32 Bio and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.37 beat Q32 Bio's score of 0.20 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Q32 Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, QTTB or OMER?

Q32 Bio has higher revenue and earnings than Omeros. Q32 Bio is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 5.84 $29.82M $3.00 3.51 Omeros N/A N/A -$3.35M $1.28 13.96

Is QTTB or OMER more profitable?

Q32 Bio's return on equity of 50.17% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Omeros N/A -164.92% 69.41%

Does the media prefer QTTB or OMER?

In the previous week, Q32 Bio had 3 more articles in the media than Omeros. MarketBeat recorded 4 mentions for Q32 Bio and 1 mentions for Omeros. Omeros' average media sentiment score of 1.29 beat Q32 Bio's score of 0.20 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omeros 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Q32 Bio (QTTB) Competitors

$10.54 -0.32 (-2.95%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.89 +0.35 (+3.32%)

As of 09/18/2026 07:30 PM Eastern

Compare

QTTB vs. CGEM, VOR, RARE, ORIC, and OMER

Should you buy Q32 Bio stock or one of its competitors? Q32 Bio's main competitors and comparable companies include Cullinan Therapeutics (CGEM), Vor Biopharma (VOR), Ultragenyx Pharmaceutical (RARE), Oric Pharmaceuticals (ORIC), and Omeros (OMER). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Q32 Bio compare to Cullinan Therapeutics?

Q32 Bio (NASDAQ:QTTB) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Q32 Bio's return on equity of 50.17% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Cullinan Therapeutics	N/A	-52.89%	-48.18%

In the previous week, Cullinan Therapeutics had 13 more articles in the media than Q32 Bio. MarketBeat recorded 17 mentions for Cullinan Therapeutics and 4 mentions for Q32 Bio. Cullinan Therapeutics' average media sentiment score of 0.69 beat Q32 Bio's score of 0.20 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cullinan Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Q32 Bio has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market.

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 34.5% of Q32 Bio shares are held by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Q32 Bio has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	5.84	$29.82M	$3.00	3.51
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A

Q32 Bio currently has a consensus price target of $31.00, suggesting a potential upside of 194.12%. Cullinan Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 56.55%. Given Q32 Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Q32 Bio is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Q32 Bio beats Cullinan Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Q32 Bio compare to Vor Biopharma?

Q32 Bio (NASDAQ:QTTB) and Vor Biopharma (NASDAQ:VOR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 34.5% of Q32 Bio shares are held by insiders. Comparatively, 0.3% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Q32 Bio has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	5.84	$29.82M	$3.00	3.51
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Q32 Bio presently has a consensus target price of $31.00, indicating a potential upside of 194.12%. Vor Biopharma has a consensus target price of $43.38, indicating a potential upside of 102.69%. Given Q32 Bio's higher probable upside, equities research analysts plainly believe Q32 Bio is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Vor Biopharma	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Q32 Bio had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 4 mentions for Q32 Bio and 2 mentions for Vor Biopharma. Q32 Bio's average media sentiment score of 0.20 beat Vor Biopharma's score of 0.00 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Q32 Bio's return on equity of 50.17% beat Vor Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Vor Biopharma	N/A	N/A	N/A

Q32 Bio has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

Summary

Q32 Bio beats Vor Biopharma on 7 of the 12 factors compared between the two stocks.

How does Q32 Bio compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Ultragenyx Pharmaceutical currently has a consensus target price of $34.42, suggesting a potential upside of 137.22%. Q32 Bio has a consensus target price of $31.00, suggesting a potential upside of 194.12%. Given Q32 Bio's stronger consensus rating and higher possible upside, analysts plainly believe Q32 Bio is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 32 more articles in the media than Q32 Bio. MarketBeat recorded 36 mentions for Ultragenyx Pharmaceutical and 4 mentions for Q32 Bio. Ultragenyx Pharmaceutical's average media sentiment score of 0.74 beat Q32 Bio's score of 0.20 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	12 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Q32 Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 34.5% of Q32 Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Q32 Bio has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	2.13	-$575M	-$5.84	N/A
Q32 Bio	$53.74M	5.84	$29.82M	$3.00	3.51

Q32 Bio has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Q32 Bio's return on equity of 50.17% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
Q32 Bio	N/A	50.17%	29.49%

Summary

Q32 Bio beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks.

How does Q32 Bio compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Oric Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.Comparatively, Q32 Bio has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

In the previous week, Q32 Bio had 1 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 4 mentions for Q32 Bio and 3 mentions for Oric Pharmaceuticals. Oric Pharmaceuticals' average media sentiment score of 0.37 beat Q32 Bio's score of 0.20 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Q32 Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Q32 Bio has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A
Q32 Bio	$53.74M	5.84	$29.82M	$3.00	3.51

Oric Pharmaceuticals presently has a consensus target price of $19.60, indicating a potential upside of 53.24%. Q32 Bio has a consensus target price of $31.00, indicating a potential upside of 194.12%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts plainly believe Q32 Bio is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Q32 Bio's return on equity of 50.17% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.35%	-33.39%
Q32 Bio	N/A	50.17%	29.49%

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Comparatively, 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Q32 Bio beats Oric Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Q32 Bio compare to Omeros?

Q32 Bio (NASDAQ:QTTB) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 34.5% of Q32 Bio shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Q32 Bio has higher revenue and earnings than Omeros. Q32 Bio is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	5.84	$29.82M	$3.00	3.51
Omeros	N/A	N/A	-$3.35M	$1.28	13.96

Q32 Bio's return on equity of 50.17% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Omeros	N/A	-164.92%	69.41%

Q32 Bio has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Omeros has a beta of 2.6, suggesting that its stock price is 160% more volatile than the broader market.

In the previous week, Q32 Bio had 3 more articles in the media than Omeros. MarketBeat recorded 4 mentions for Q32 Bio and 1 mentions for Omeros. Omeros' average media sentiment score of 1.29 beat Q32 Bio's score of 0.20 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omeros	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Q32 Bio presently has a consensus target price of $31.00, suggesting a potential upside of 194.12%. Omeros has a consensus target price of $38.00, suggesting a potential upside of 112.65%. Given Q32 Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Q32 Bio is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Q32 Bio beats Omeros on 9 of the 14 factors compared between the two stocks.

Get Q32 Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QTTB vs. The Competition

Export

Metric	Q32 Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$313.77M	$3.89B	$7.24B	$13.21B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	3.51	14.23	275.49	25.40
Price / Sales	5.84	1,419.61	639.63	86.88
Price / Cash	6.95	108.90	76.25	51.42
Price / Book	3.09	15.45	10.46	6.33
Net Income	$29.82M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-5.05%	-1.21%	0.59%	1.12%
1 Month Performance	-33.54%	-3.29%	-1.74%	-2.39%
1 Year Performance	469.73%	37.74%	18.13%	5.35%

Q32 Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QTTB Q32 Bio	3.6953 of 5 stars	$10.54 -2.9%	$31.00 +194.1%	+469.7%	$313.77M	$53.74M	3.51	22	Analyst Forecast
CGEM Cullinan Therapeutics	3.3763 of 5 stars	$20.54 +0.7%	$33.00 +60.7%	+240.0%	$1.32B	N/A	N/A	109
VOR Vor Biopharma	1.3298 of 5 stars	$22.32 -3.3%	$43.38 +94.3%	-21.4%	$1.32B	N/A	N/A	76	News Coverage
RARE Ultragenyx Pharmaceutical	3.396 of 5 stars	$13.07 -4.0%	$36.63 +180.3%	-48.4%	$1.29B	$673M	N/A	1,371	Trending News Analyst Forecast High Trading Volume
ORIC Oric Pharmaceuticals	2.3401 of 5 stars	$12.36 -2.3%	$19.60 +58.6%	+21.1%	$1.28B	N/A	N/A	111	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QTTB) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Q32 Bio (QTTB) Competitors

QTTB vs. CGEM, VOR, RARE, ORIC, and OMER

How does Q32 Bio compare to Cullinan Therapeutics?

Summary

How does Q32 Bio compare to Vor Biopharma?

Summary

How does Q32 Bio compare to Ultragenyx Pharmaceutical?

Summary

How does Q32 Bio compare to Oric Pharmaceuticals?

Summary

How does Q32 Bio compare to Omeros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Q32 Bio (QTTB) Competitors

QTTB vs. CGEM, VOR, RARE, ORIC, and OMER

How does Q32 Bio compare to Cullinan Therapeutics?

Is QTTB or CGEM more profitable?

Does the media favor QTTB or CGEM?

Which has more volatility & risk, QTTB or CGEM?

Do insiders and institutionals hold more shares of QTTB or CGEM?

Which has better valuation and earnings, QTTB or CGEM?

Do analysts recommend QTTB or CGEM?

Summary

How does Q32 Bio compare to Vor Biopharma?

Do insiders & institutionals believe in QTTB or VOR?

Which has preferable valuation and earnings, QTTB or VOR?

Do analysts recommend QTTB or VOR?

Does the media favor QTTB or VOR?

Is QTTB or VOR more profitable?

Which has more volatility and risk, QTTB or VOR?

Summary

How does Q32 Bio compare to Ultragenyx Pharmaceutical?

Do analysts rate RARE or QTTB?

Which has more volatility & risk, RARE or QTTB?

Does the media prefer RARE or QTTB?

Do institutionals and insiders hold more shares of RARE or QTTB?

Which has stronger valuation and earnings, RARE or QTTB?

Is RARE or QTTB more profitable?

Summary

How does Q32 Bio compare to Oric Pharmaceuticals?

Which has more volatility & risk, ORIC or QTTB?

Does the media favor ORIC or QTTB?

Which has better earnings and valuation, ORIC or QTTB?

Do analysts prefer ORIC or QTTB?

Is ORIC or QTTB more profitable?

Do institutionals & insiders believe in ORIC or QTTB?

Summary

How does Q32 Bio compare to Omeros?

Do institutionals & insiders hold more shares of QTTB or OMER?

Which has higher valuation & earnings, QTTB or OMER?

Is QTTB or OMER more profitable?

Which has more volatility and risk, QTTB or OMER?

Does the media prefer QTTB or OMER?

Do analysts rate QTTB or OMER?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB vs. The Competition

Q32 Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools